

#### Executive Summary

This final report reflects the collaboration within the EPAD Consortium to achieve the communication and dissemination objectives of the project during the period referred to. It provides a compilation of all communication and dissemination activities undertaken in the project, and tools produced to support these activities. Evaluation of impact is also included.

The first section of this deliverable focuses on the assessment of the communication strategy described in the Deliverable D6.1 (Initial Communication Plan, including project branding and policies) and Deliverable D6.4 (Updated communication plan, tools and materials). Communication objectives were analysed as well as the defined target audiences.

Overall, we were quite successful by achieving our objectives and reaching out to the defined target audiences. We managed to implement a various range of communication and dissemination activities. To illustrate the favorable outcome of our communication plan, success indicators were set to evaluate communication tools and activities conducted during the lifespan of the project. Furthermore, this report gives information on how the EPAD project was engaged with the dementia community, young researchers and related initiatives.

The second section consists of the assessment of the EPAD Description of Work (DoW) featuring an overview of communication requirements, deliverables and responsibilities. The third part includes an assessment of the impact of the project. External evaluators were asked to assess the impact of the project and its communication activities by providing some qualitative feedback (i.e. strengths and weaknesses of the different communication tools and activities).

Finally, this report describes the sustainability of the communication activities that should result from the EPAD project. For projects to be sustained, various tools need to be sustained or set.

**For more information:** [info@epad.org](mailto:info@epad.org)





innovative  
medicines  
initiative

This work has received support from the  
EU/EFPIA Innovative Medicines Initiative Joint  
Undertaking (EPAD grant n°115736).

